Martino E, Bartalena L, Mariotti S, Aghini-Lombardi F, Ceccarelli C, Lippi F, Piga M, Loviselli A, Braverman L, Safran M
Istituto di Medicina Interna, Cattedra di Endocrinologia, University of Cagliari, Italy.
Acta Endocrinol (Copenh). 1988 Oct;119(2):167-73. doi: 10.1530/acta.0.1190167.
Amiodarone, an iodine-rich drug, represents at the present, at least in Europe, one of the most common sources of iodine-induced thyroid dysfunction. The drug may induce both hypothyroidism and thyrotoxicosis. In spite of the large iodine intake occurring during amiodarone therapy, 131I thyroid uptake is detectable in patients with amiodarone-iodine-induced hypothyroidism, irrespective of the presence or absence of underlying thyroid disease. In contrast, in patients with amiodarone-iodine-induced thyrotoxicosis, 131I thyroid uptake is normal or even elevated in those with co-existent underlying thyroid disorders, whereas it is very low in those with an apparently normal thyroid gland. Perchlorate discharge test was performed in 8 patients with hypothyroidism and in 5 patients with hyperthyroidism induced by amiodarone: a positive test was found in all hypothyroid patients and a negative test in all hyperthyroid patients.
胺碘酮是一种富含碘的药物,目前至少在欧洲,它是碘致甲状腺功能障碍最常见的来源之一。该药物可引发甲状腺功能减退和甲状腺毒症。尽管在胺碘酮治疗期间会摄入大量碘,但在胺碘酮 - 碘所致甲状腺功能减退患者中,无论是否存在潜在甲状腺疾病,均可检测到131I甲状腺摄取。相反,在胺碘酮 - 碘所致甲状腺毒症患者中,合并潜在甲状腺疾病者的131I甲状腺摄取正常甚至升高,而甲状腺看似正常者的131I甲状腺摄取则非常低。对8例胺碘酮所致甲状腺功能减退患者和5例胺碘酮所致甲状腺功能亢进患者进行了过氯酸盐释放试验:所有甲状腺功能减退患者试验结果为阳性,所有甲状腺功能亢进患者试验结果为阴性。